About Pricing FAQs Blog

Loading clinical trials...

Your health journey, clearly organized.

Find Clinical Trials →

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Back to clinical trial search

COMPLETEDPhase 2NCT04146896

Efficacy and Safety of NYX-2925 in Subjects With Neuropathic Pain Associated With Diabetic Peripheral Neuropathy (DPN)

To evaluate the efficacy of NYX-2925 versus placebo in treating the neuropathic pain associated with diabetic peripheral neuropathy.

Lead sponsor: Aptinyx•35 U.S. locations•View source on ClinicalTrials.gov

Clareo plain-language summary

What this study is about

Generating AI summary...

Save this trial guide to your notes

Keep your clinical trial research organized — questions to ask, what to expect, and key details.

Sponsors

Lead Sponsor

Aptinyx

Collaborators

Worldwide Clinical Trials

This is a randomized, double-blind, placebo-controlled study to assess the efficacy and safety of NYX-2925 in subjects with neuropathic pain associated with diabetic peripheral neuropathy. The study will be a 13- to 16-week study, including a 1- to 4-week Screening Period, followed by a 12- week double-blind, randomized, placebo-controlled Treatment Period.

Age

18 - 75 years

Sex

ALL

Healthy Volunteers

No

Inclusion Criteria

•Informed consent
•Subject has diabetic peripheral neuropathy of symmetrical nature in lower extremities for ≥4 years and reports at least moderate pain over the last week
•Stable diabetic and protocol allowed medication during the study
•Agrees to use highly effective birth control during the study
•Has not participated in an interventional study for at least 30 days and agrees not to participate in another interventional study during the study

Exclusion Criteria

•Pain due to other conditions or diseases that would complicate participation in the study or pain reporting
•Current or historical serious medical conditions
•Prior participation in NYX-2925 clinical trial

Related studies

RECRUITINGPhase 3

Evaluation of Efficacy and Safety of Suzetrigine (SUZ) for Pain Associated With Diabetic Peripheral Neuropathy

NCT07231419 · Diabetic Peripheral Neuropathic Pain

RECRUITINGPhase 2

SPENDD: Quantitative Sensory Testing and Analgesic Response for Painful Peripheral Neuropathy.

NCT06614322 · Painful Peripheral Neuropathy, Diabetic Peripheral Neuropathic Pain (DPN), and more

RECRUITINGPhase 2

A Chronic Pain Master Protocol (CPMP): A Study of LY4065967 in Participants With Diabetic Peripheral Neuropathic Pain

NCT07285018 · Diabetic Peripheral Neuropathic Pain

RECRUITINGPhase 2

Evaluate the Efficacy and Safety of JMKX000623 in Participants With Diabetic Peripheral Neuropathic Pain

NCT06221241 · Diabetic Peripheral Neuropathic Pain

Not Yet RecruitingPhase 1

A Study of HRS-2129 in Patients With Diabetic Peripheral Neuropathic Pain

NCT07377721 · Diabetic Peripheral Neuropathic Pain

View all related studies →

Data from ClinicalTrials.govLast updated on ClinicalTrials.gov: April 28, 2023Terms

Trial snapshot

StatusCOMPLETED

PhasePHASE2

Enrollment228

Start dateNov 2019

Last updatedApr 28, 2023

Condition

Diabetic Peripheral Neuropathic Pain

Locations shown

Aptinyx Clinical Site

Fresno, California

Aptinyx Clinical Site

Irvine, California

Aptinyx Clinical Site

Lomita, California

For caregivers

Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.

Start free trial →

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: April 28, 2023Data synced to Clareo: May 25, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions